229
Participants
Start Date
July 6, 2017
Primary Completion Date
December 2, 2022
Study Completion Date
September 13, 2023
Elimusertib (BAY1895344)
Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
Kantonsspital St. Gallen, Sankt Gallen
Hôpital Cantonal Universitaire de Genève, Geneva
Oncology Institute of Southern Switzerland, Bellinzona
Weill Cornell Medical College, New York
Jefferson Medical College, Philadelphia
Fairfax-Northern Virginia Hematology/Oncology, PC, Fairfax
Emory University, Atlanta
H. Lee Moffitt Cancer Center & Research Institute, Tampa
University Hospitals Cleveland Medical Center, Cleveland
Gabrail Cancer Center, Canton
Texas Oncology- San Antonio Northeast, San Antonio
University of Utah - Oncology, Salt Lake City
City of Hope National Medical Center, Duarte
US Oncology / Eugene, Eugene
Beijing Cancer Hospital, Beijing
National University Hospital, Singapore
National Cancer Center Singapore, Singapore
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
University of Texas MD Anderson Cancer Center, Houston
Cross Cancer Institute, Edmonton
OHRI - The Ottawa Hospital, Ottawa
Integrated Cancer Center of the CHU de Québec, Québec
National Cancer Center Hospital East, Kashiwa
Shizuoka Cancer Center, Sunto
National Cancer Center Hospital, Chuo-ku
Velindre Hospital, Cardiff
Royal Marsden NHS Trust (Surrey), Sutton
Freeman Hospital, Newcastle upon Tyne
Lead Sponsor
Bayer
INDUSTRY